Global Allergy and Asthma European Network (GA²LEN) addresses the epidemic of allergy and asthma

Czech version

Authors: Petr Panzner ¹; Petr Čáp ²; Peter Burney ³; Torsten Zuberbier ⁴; Paul Van Cauvenberg ⁵; Jean Bousquet ⁶
Authors‘ workplace: Univerzita Karlova v Praze, Lékařská fakulta Plzeň. Ústav imunologie a alergologie ¹; Členové GALEN (Globální evropské sítě pro léčbu alergií a astmatu), projektu podporovaném z fondů Evropské unie pro výzkum (6. rámcový program), smlouva č. FOOD-CT-2004-506378. ²; Nemocnice Na Homolce, Oddělení imunologie a alergologie, Praha ²; National Heart and Lung Institute, Imperial College, Respiratory Epidemiology and Public Health, London, UK ³; Allergy Centre Charité, Charité – Universitätsmedizin Berlin, Germany ⁴; Ghent University, Belgium ⁵; University Hospital, Hôpital Arnaud de Villeneuve, Montpellier, and INSERM U780, France ⁶
Published in: Čas. Lék. čes. 2010; 149: 32-37
Category: Special Articles

Overview

Allergic diseases represent a major health problem in Europe. They are increasing in prevalence, severity and costs. GA²LEN, an FP6 Network of Excellence, was created in 2005 as a vehicle to ensure excellence in research bringing together research and clinical institutions to combat fragmentation in the European research area and to tackle Allergy in its globality. GA²LEN benefited greatly from the voluntary efforts of researchers who are strongly committed to this model of pan-European collaboration. The network was organized in order to increase networking for scientific projects in allergy and asthma around Europe and to make GA²LEN the world leader in the field. Besides these activities, research has been jointly made and the first papers are being published. GA²LEN achievements in general can be grouped as those for a durable infrastructure built up during the project phase those which are project-related work based on these novel infrastructures, and the development and implementations of guidelines. The major achievements of GA²LEN are reported in this paper.

Key words:
GA²LEN, asthma, allergy, European Union.

Sources

1. Bousquet J, Khaltaev N. Global surveillance, prevention and control of Chronic Respiratory Diseases. A comprehensive approach. Global Alliance against Chronic Respiratory Diseases. World Health Organization 2007: 148.

2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl 5): S147–S334.

3. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8–160.*

4. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007; 120: 381–387.

5. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372: 1049–1057.

6. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008; 63: 670–684.

7. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006; 117: 158–162.

8. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005; 60: 788–794.

9. Zuberbier T, Lötvall J. Allergies have a socio-economic impact. European Academy of Allergology and Clinical Immunology, annual meeting. Barcelona June 2008. Allergy 2008; (Suppl 84).*

10. 2008–2013 Action plan for the global strategy for the prevention and control of non communicable diseases. Prevent and control cardiovascular diseases, cancers, chronic respiratory diseases, diabetes. http://wwwwhoint/nmh/Actionplan-PC-NCD-2008pdf. 2008.

11. Bousquet J, Bieber T, Fokkens W, Kowalski ML, Humbert M, Niggemann B, et al. Important questions in allergy: novel research areas. Allergy 2008; 63: 143–147.*

12. Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy 2008; 63: 842–853.*

13. Demoly P, Pichler W, Pirmohamed M, Romano A. Important questions in Allergy: 1-drug allergy/hypersensitivity. Allergy 2008; 63: 616–619.*

14. Bachert C, et al. Important research questions in allergy and related diseases. 3-chronic rhinonsinusitis and nasal polyposis – a GALEN study. Allergy 2009; 64: 520–533.*

15. van Cauwenberge P, Watelet JB, Van Zele T, Bousquet J, Burney P, Zuberbier T. Spreading excellence in allergy and asthma: the GA2LEN (Global Allergy and Asthma European Network) project. Allergy 2005; 60: 858–864.*

16. Warner JO. Global Allergy and Asthma European Network (GA2LEN) – a focus for paediatric allergy research. Pediatr Allergy Immunol 2006; 17: 163.

17. Frew AJ. GA2LEN – The Global Allergy and Asthma European Network. Clin Exp Allergy 2005; 35: 122–125.

18. Heinzerling L, Frew AJ, Bindslev-Jensen C, Bonini S, Bousquet J, Bresciani M, et al. Standard skin prick testing and sensitization to inhalant allergens across Europe – a survey from the GALEN network. Allergy 2005; 60: 1287–1300.*

19. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Dahlen B, Dahlen S, et al. Aspirin provocation tests for diagnosis of aspirin sensitivity. EAACI/GA2LEN guideline. Allergy 2007; 62: 1111–1118.*

20. Turjanmaa K, Darsow U, Niggemann B, Rance F, Vanto T, Werfel T. EAACI/GA2LEN position paper: present status of the atopy patch test. Allergy 2006; 61: 1377–1384.*

21. Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rance F, Turjanmaa K, et al. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. Allergy 2007; 62: 723–728.*

22. Carlsen KH, Anderson SD, Bjermer L, Bonini S, Brusasco V, Canonica W, et al. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN. Allergy 2008; 63: 492–505.*

23. Carlsen KH, Anderson SD, Bjermer L, Bonini S, Brusasco V, Canonica W, et al. Exercise induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 2008; 63: 387–403.*

24. Bonini S, Rasi G, Brusasco V, Carlsen KH, Crimi E, Popov T, et al. Nonspecific provocation of target organs in allergic diseases: EAACI-GA(2)LEN consensus report. Allergy 2007; 62: 683–694.*

25. Burney P, Potts J, Makowska J, Kowalski M, Phillips J, Gnatiuc L, et al. A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy 2008; 63: 865–871.*

26. Shaheen S, Potts J, Gnatiuc L, Makowska J, Kowalski ML, Joos G, et al. The relation between paracetamol use and asthma: a GA2LEN European case-control study. Eur Respir J 2008; 32: 1231–1236.*

27. Keil T, Kulig M, Simpson A, Custovic A, Wickman M, Kull I, et al. European birth cohort studies on asthma and atopic diseases: I. Comparison of study designs – a GALEN initiative. Allergy 2006; 61: 221–228.*

28. Keil T, Kulig M, Simpson A, Custovic A, Wickman M, Kull I, et al. European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures – a GALEN initiative. Allergy 2006; 61: 1104–1111.*

29. Eller E, Roll S, Chen CM, Herbarth O, Wichmann HE, von Berg A, et al. Meta-analysis of determinants for pet ownership in 12 European birth cohorts on asthma and allergies: a GA2LEN initiative. Allergy 2008; 63: 1491–1498.*

30. Almqvist C, Worm M, Leynaert B. Impact of gender on asthma in childhood and adolescence: a GA2LEN review. Allergy 2008; 63: 47–57.*

31. Tricon S, Willers S, Smit H, Burney P, Devereux A, Frew A, et al. Nutrition and allergic diseases. Clin Exp Rev 2006; 6: 117–188.*

32. Papadopoulos NG, Xepapadaki P, Mallia P, Brusselle G, Watelet JB, Xatzipsalti M, et al. Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy 2007; 62: 457–470.*

33. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10- secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205: 2887–2898.*

34. Brunekreef B. Environmental epidemiology and risk assessment. Toxicol Lett 2008; 180: 118–122.

35. Brunekreef B. Health effects of air pollution observed in cohort studies in Europe. J Expo Sci Environ Epidemiol 2007; 17 (Suppl 2): S61–S65.*

36. Madsen C, Lodrup-Carlsen K, Hoek G, Oftedal B, Nasdaf P, Meliefste K, et al. Modeling the intraurban variability of outdoor traffic pollution in Oslo, Norway – A GA2LEN study. Atmosph Environ 2007; 41: 7500–7511.*

37. Aguilera I, Sunyer J, Fernandez–Patier R, Hoek G, Aguirre-Alfaro A, Meliefste K, et al. Estimation of outdoor NO(x), NO(2), and BTEX exposure in a cohort of pregnant women using land use regression modeling. Environ Sci Technol 2008; 42: 815–821.*

38. Kogevinas M, Zock JP, Jarvis D, Kromhout H, Lillienberg L, Plana E, et al. Exposure to substances in the workplace and new–onset asthma: an international prospective population–based study (ECRHS–II). Lancet 2007; 370: 336–341.

39. Radon K, Gerhardinger U, Schulze A, Zock JP, Norback D, Toren K, et al. Occupation and adult onset of rhinitis in the general population. Occup Environ Med 2008; 65: 38–43.*

40. Medina-Ramon M, Zock JP, Kogevinas M, Sunyer J, Basagana X, Schwartz J, et al. Short-term respiratory effects of cleaning exposures in female domestic cleaners. Eur Respir J 2006; 27: 1196–1203.

41. Radon K, Huemmer S, Dressel H, Windstetter D, Weinmayr G, Weiland S, et al. Do respiratory symptoms predict job choices in teenagers? Eur Respir J 2006; 27: 774–778.

42. Riu E, Dressel H, Windstetter D, Weinmayr G, Weiland S, Vogelberg C, et al. First months of employment and new onset of rhinitis in adolescents. Eur Respir J 2007; 30: 349–355.

43. Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Crameri R, et al. Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GALEN project. Allergy 2006; 61: 671–680.*

44. Bousquet PJ, Chatzi L, Jarvis D, Burney P. Assessing skin prick tests reliability in ECRHS-I. Allergy 2008; 63: 341–346.*

45. Bousquet PJ, Hooper R, Kogevinas M, Jarvis D, Burney P. Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I. Clin Exp Allergy 2007; 37: 780–787.*

46. Bousquet PJ, Leynaert B, Neukirch F, Sunyer J, Janson CM, Anto J, et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I. Allergy 2008; 63: 1301–1309.*

47. Watelet JB, Van Zele T, Gjomarkaj M, Canonica GW, Dahlen SE, Fokkens W, et al. Tissue remodelling in upper airways: where is the link with lower airway remodelling? Allergy 2006; 61: 1249–1258.*

48. Gagliardo R, La-Grutta S, Chanez P, Profita M, Paterno A, Cibella F, et al. Noninvasive markers of airway inflammation and remodeling in childhood asthma. Pediatr Allergy Immunol 2009 (in press).

49. Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008; 63: 1054–1060.

50. Carlsen KH, Kowalski ML. Asthma, allergy, the athlete and the Olympics. Allergy 2008; 63: 383–386.*

51. Baiardini I, Braido F, Brandi S, Tarantini F, Bonini S, Bousquet PJ, et al. The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA(2)LEN review. Allergy 2008; 63: 1015–1030.*

52. Baiardini I, Braido F, Tarantini F, Porcu A, Bonini S, Bousquet PJ, et al. ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008; 63: 660–669.*

53. Bousquet J, Zuberbier T, Mullol J. ACCEPT-1 Study Group icwGL. Improvement in diseasespecific quality of life and reduced symptom burden measured with a visual analogue scale in subjects with intermittent allergic rhinitsi treated with desloratadine. Allergy 2008; 62 (Suppl 64).*

54. Bousquet J, del-Carpio J, Group A-S. Improvement in disease-specific quality of life and reduced symptom burden measured with a visual analogue scale in subjects with persistent allergic rhinitsi treated with desloratadine. American College of Allergy, Asthma and Immunology, Seattle, November 2008.*

55. Kabesch M. Gene by environment interactions and the development of asthma and Allergy Toxicol Lett 2006; 162: 43–48.

56. Kauffmann F, Cambon-Thomsen A. Tracing biological collections: between books and clinical trials. JAMA 2008; 299: 2316–2318.*

57. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, et al. ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol 2006; 117: 1054–1062.*

58. Bonini S, Bonini M, Bousquet J, Brusasco V, Canonica GW, Carlsen KH, et al. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy 2006; 61: 681–692.*

59. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62 (Suppl 84): 1–41.*

60. Bousquet J, Bindslev-Jensen C, Canonica GW, Fokkens W, Kim H, Kowalski M, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59 (Suppl 77): 4–16.*

61. Bousquet J, van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GALEN). Allergy 2006; 61: 1086–1096.*

62. Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy 2005; 60: 1112–1115.*

63. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119: 881–891.*

64. van Weel C. General practitioners’ central role in management of asthma and allergic rhinitis. Allergy 2008; 63: 1005–1007.

65. Ryan D, van Weel C, Bousquet J, Toskala E, Ahlstedt S, Palkonen S, et al. Primary care: the cornerstone of diagnosis of allergic rhinitis. Allergy 2008; 63: 981–989.*

66. Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P, et al. Allergic rhinitis management pocket reference 2008. Allergy 2008; 63: 990–996.*

67. Zuberbier T, Worm M. Allergies and the skin, an interdisciplinary approach in GA(2)LEN and EAACI activities. Allergy 2006; 61: 1373–1376.*

68. Zuberbier T, Bindslev–Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61: 321–331.*

69. Zuberbier T, Bindslev–Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316–320.*

70. Brozek JL, Baena-Cagnani CE, Bonini S, Canonica GW, Rasi G, van Wijk RG, et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008; 63: 38–46.*

* práce ve spolupráci GA2LEN

Labels

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pneumology and ftiseology Pain management

Debts in patients with addictive diseases are health and social problem

HOX genes and the limb development in the clinical praxis and in the experiment

Role of microRNAs in the immune system

Male fertility and cancer treatment

Education in schizophrenia: How patients and their relatives assess the relapse prevention programme PREDUKA

Assessment of health state and working capacity of people suffering from mental disorders and behaviour disorders

Article was published in